Hit HIV-1 hard, but only when necessary

@article{Harrington2000HitHH,
  title={Hit HIV-1 hard, but only when necessary},
  author={Mark Harrington and Charles C. J. Carpenter},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={2147-2152}
}
COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS
TLDR
Changes in cholesterol or quality of life associated with antiretroviral therapy do not justify limiting access to early HIV treatment, and the effect of fat redistribution symptoms on quality-of-life will determine the optimal choice of early vs deferred therapy for an individual patient.
Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives.
TLDR
Various obstacles to HIV therapy are discussed, and perspectives relating to these issues that are critical in determining the success or failure of HAART are provided.
Treatment of AIDS and HIV-related conditions: 2001.
TLDR
Clinicians are advised to refer to the excellent federal guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents and for prevention of opportunistic infections, which are updated frequently on the Internet (Table 2).
The antiretroviral-experienced patient.
TLDR
It may be reasonable to stop ARV therapy among asymptomatic patients with high CD4 cell counts and low viral loads and carefully monitor them and continuation of an optimized regimen in the patient with a multidrug resistant (MDR) virus is the best strategy.
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
TLDR
Overall, GTI were not as safe as continuing therapy, despite achieving some improvements in quality of life, and GTI did not reduce the overall rate of management-related adverse events.
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study
TLDR
The rationale and methods of the Strategic Timing of AntiRetroviral Treatment (START) study are outlined, an ongoing multicenter international trial designed to assess the risks and benefits of initiating ART earlier than is currently practiced and addressing one of the most important questions in the clinical management of ART.
How HIV treatment could result in effective prevention.
TLDR
It is conceivable that, in the future, HAART will be an integral part of both individual-level clinical treatment programs as well as public health-based HIV prevention interventions.
[Antiviral treatment regimens].
  • S. Esser
  • Medicine, Biology
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • 2006
TLDR
The availability and use of effective antiretroviral combination therapies has dramatically decreased the morbidity and mortality of HIV infection, and HIV infection can be better treated.
Management of HIV-1 Infection in Adults and Adolescents
The management of Human Immunodeficiency Virus-1 (HIV-1) infection has undergone dramatic change since its initial identification. Advances have occurred in drug development, viral pathology
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Benchmarks for antiretroviral therapy.
TLDR
This conclusion follows from the rapid exponential decay of plasma viremia following initiation of HAART and the fact that the antiretroviral drugs employed block infection of new cells but do not affect viral RNA expression in cells that are already infected.
Strategies for long-term success in the treatment of HIV infection.
TLDR
The treatment of drug-resistant patients is challenging; the best way to deal with resistance is to prevent it.
Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions
TLDR
The hypothesis was that the virologic response to HAART would be substantially worse among unselected patients in an inner-city clinic than among patients enrolled in clinical trials, and this study analyzed data from a cohort of protease inhibitor-naive patients in whom HAART was initiated in the clinic between March 1996 and February 1998.
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
TLDR
Baseline plasma viremia emerged as the factor most tightly correlated with the duration of treatment required, allowing us to estimate the required time as a function of this one measure.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
TLDR
In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes, and generally did not show mutations associated with resistance to the relevant antiretroviral drugs.
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
TLDR
Functional HIV-1-specific CD4+ T cells are commonly available for support of anti-HIV-1 effector responses in active disease, but their decline with anti-retroviral therapy indicates that immunologic participation in long-term HIV- 1 control will probably require effective vaccination strategies.
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
Highly active antiretroviral therapy (HAART) increases CD4(+) cell numbers, but its ability to correct the human immunodeficiency virus (HIV)-induced immune deficiency remains unknown. A three-phase
Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study.
TLDR
HIV-infected injecting drug users and those with lower levels of educational attainment start HAART later than other patient groups, and the deferred initiation of therapy in these patients does not appear to translate into an increased risk of clinical disease progression.
Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
TLDR
Data indicate that the loss of CMV-specific CD4+ lymphocyte responses in individuals infected with HIV-1 who have active CMV EOD may be restored after ganciclovir therapy and HAART, which provides evidence for functional immune reconstitution to an important pathogen.
...
1
2
3
...